&nbsp;

Sep 2025

Drug

PANitumumab

Other Name(s): Vectibix®

Quick Link(s):

Jan 2025

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Jun 2025

Drug

pegylated liposomal DOXOrubicin

Other Name(s): Caelyx®

Quick Link(s):

Sep 2025

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Jun 2025

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Sep 2025

Drug

siltuximab

Other Name(s): Sylvant®

Quick Link(s):

Mar 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Jul 2025

Regimen

PGLDX

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PGLDX

Cancer Type:

Sarcoma,

Kaposi's Sarcoma

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

IRIN+CETU; IRIN(Q2W)+CETU

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

cetuximab,

irinotecan

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma

Drugs Used:

riTUXimab